PATENT CLAIM ANALYSIS

Application Number: 16097182
Application Type: Utility
Filing Date: 2018-10
Publication Date: 2019-05
Patent Classification: ["424", "204100"]

Abstract:
The present invention relates to compositions, immunogenic or vaccine compositions and pharmaceutical compositions for the prevention or treatment of peanut allergy in humans. Furthermore, the invention provides methods for preventing or treating of peanut allergy in humans.

Claim (Index 1):
A composition comprising\n (a) a modified virus-like particle (VLP) with at least one first attachment site, wherein said modified VLP comprises, essentially consists of, or consists of, at least one modified VLP polypeptide, wherein said modified VLP polypeptide comprises, or preferably consists of,\n a) a VLP polypeptide, and \n b) a T helper cell epitope,\n wherein said VLP polypeptide comprises, or preferably consists of, \n (i) an amino acid sequence of a coat protein of a virus, preferably an amino acid sequence of a coat protein of a plant virus; or \n (ii) a mutated amino acid sequence, wherein the amino acid sequence to be mutated is an amino acid sequence of said coat protein of a virus, and wherein said mutated amino acid sequence and said coat protein of a virus show a sequence identity of at least 90%, preferably of at least 95%, further preferably of at least 98% and again more preferably of at least 99%; and \n \n (b) at least one peanut allergen with at least one second attachment site, wherein preferably said peanut allergen is selected from the peanut allergens, and isoforms thereof, of Ara h1, Ara h2, Ara h3 and Ara h6 and proteins with an amino acid sequence of at least 90%, preferably of at least 92%, further preferably of at least 95%, and again further preferably of at least 98% amino acid sequence identity with said peanut allergens and isoforms thereof; and wherein further preferably said peanut allergen comprises, or preferably consists of, a protein with the amino sequence selected from SEQ ID NO:18; SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:25. SEQ ID NO's:26-28 or SEQ ID NO:30, or a protein with an amino acid sequence of at least 90%, preferably of at least 92%, further preferably of at least 95%, and again further preferably of at least 98% amino acid sequence identity with SEQ ID NO:18; SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:25, SEQ ID NO's:26-28 or SEQ ID NO:30; wherein (a) and (b) are linked through said at least one first and said at least one second attachment site via at least one non-peptide covalent bond.

Metadata:
- Claim Count in Document: 50.0
- Percentile: 97.0
- Lexical Diversity: 1.51852
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15758052', '15520676', '13982986', '11601687', '12443344']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7319578548959573
- 35 USC 102 Novelty (BERT): 0.5760368138856864
- Combined Prediction Score: 0.7163657507949303
- Mean Citation Score: 394.389782
- Max Citation Score: 501.40494
- Similarity Product: 398.486811748327

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test